HF-158K1 by HighField Biopharmaceuticals for Colon Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Colon Cancer.

Music agency creates parody ‘Bravura’ drug ad to amplify its knack for pharma marketing scores

The new video ad for Bravura seems to have it all — a reassuring voiceover, tired and concerned patients, an overly long list of potential

November 17, 2023

Leveraging Personal Health Nurses to Connect the Dots Across the Care Continuum

Mary Bacaj, President, of Value-Based Care, Conifer Health Solutions Our nation is getting sicker. Research by the Employee Benefit Research Institute found that the number

July 7, 2023

Contradictory coverage decisions in North Carolina

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. In an

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.